SGLT-2 Therapy Center

John Anderson, MD, gives us a brief introduction to himself and talks about how, as an internal medicine specialist, he deals with a whole range of issues related to diabetes which he see in his patients. More videos with John Anderson, MD: Thoughts on SGLT-2 Inhibitors What is the ADA …

John Anderson, MD, talks about the efforts of the American Diabetes Association, and how they are using the successful experiences they have gained through landmark studies such as the Diabetes Prevention Program (DPP), applying this knowledge to new initiatives such as outreach into the community through the YMCA and other …

John Anderson, MD, talks about how clinicians should look at more than just a specific A1c number when beginning treatment for diabetes explaining that the measure is really only a way to project future risk. Factors such as family history, ethnic background and other characteristics may be more relevant. But …

John Anderson, MD, talks about the new SGLT-2 inhibitors, what he has heard so far on their efficacy, and some of the concerns that have been raised about this new class of drugs…. See more SGLT-2 Resources More videos with John Anderson, MD: John Anderson, MD, ADA Board of Directors, …

Dr. Stanley Schwartz finishes up his slides series on the current state of the obesity epidemic and its relationship with diabetes. Topics covered in this set include a discussion of the newest drug therapies on the market including the incretins and the SGLT-2 inhibitors…. To download in PowerPoint (.ppt) format: Obesity …

Quality issues in the manufacturing plant prevents final approval…. The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week. Eli Lilly and Boehringer Ingelheim said the FDA had issued a complete response …

Trade group announces 180 diabetes medicines currently in development…. The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced that biopharmaceutical research companies are currently developing 180 new medicines aimed to help those affected by diabetes. Of these drugs in development, 128 of them are indicated for diabetes and 52 …

In this special Homerun Slides presentation, details of the CANTATA-D2 study are reviewed comparing the effects and benefits of the SGLT2 inhibitors and DPP-4 inhibitors…. To download in PowerPoint (.ppt) format: SGLT2 Inhibitors for Treatment of Type 2 Diabetes See more SGLT-2 Resources

But SGLT-2 inhibitors still yield net reduction in plasma glucose, A1C, and weight…. A new class of drugs for type 2 diabetic patients known as sodium-glucose cotransporter 2 (SGLT-2) inhibitors are the latest thing used to reduce plasma glucose levels in the body. The SLGT-2 protein is responsible for about …

How does SGLT-2 inhibitor, ipragliflozon compare to metformin alone?…. Ipragliflozin is an oral medication in development by Astellas Pharma for the treatment of type 2 diabetes. A novel selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, ipragliflozin works similarly to the first in class marketed SGLT-2 inhibitor drug, canagliflozin, by increasing urinary …